Meeting Coverage


European Hematology Association

Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma

ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment

A photo of the packaging and vial of Adcetris over a computer rendering of a Reed-Sternberg cell in Hodgkin lymphoma

Latest EHA Meeting Coverage

Fixed-Duration, All-Oral Regimen Slows CLL Progression

Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil

June 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma

Better response rates and survival with axicabtagene ciloleucel versus external control group

June 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL

Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor

June 14, 2021
Combination Ups Survival in Older AML Patients

Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone

June 17, 2020
Biologic Effective in Light Chain Amyloidosis

Anti-CD38 therapy added to conventional regimen boosts PFS in trial

June 16, 2020
Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trial

Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases

June 15, 2020
New Standard for Relapsed/Refractory Multiple Myeloma?

Triplet regimen significantly extended median PFS versus doublet in IKEMA study

June 15, 2020
FLT3-ITD Inhibitor Improves Survival in Relapsed AML

More quizartinib-treated patients went on to stem cell transplant

June 19, 2018
Lymphoma Risk with JAK Inhibitors for MPNs

Preexisting aberrant B-cell clone implicated

June 18, 2018
Battle of PI3K Inhibitors for Lymphocytic Leukemia Heats Up

Three drugs produce high response rates for CLL. Is one of them safer?

June 17, 2015
One Proteasome Inhibitor Tops Another in Relapsed Myeloma

Progression-free survival doubled with carfilzomib versus bortezomib

June 15, 2015
Relapsed Myeloma Responds to Monoclonal Antibody

Durable responses with daratumumab seen after multiple prior regimens

June 14, 2015
PFS Rises in Progressive Myeloma with Targeted Biologic

Adding elotuzumab boosts median progression-free survival by almost 5 months.

June 12, 2015